Effect of intermittent hypoxia on rat INS-1 cells and the protective effect of melatonin

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 7, 2014, Pages 941-948

  Lu, W ^a,b   Liu, L ^c   Li, H ^b   Li, G ^a   Yu, N ^a   Wang, D L ^b   Wang, W ^a   Kang, J ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b No 202 Hospital of PLA   (China)

^c GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Intermittent hypoxia; Melatonin; Obstructive sleep apnea hypopnea syndrome; Oxidative stress; Pancreatic cells

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; COMPLEMENTARY DNA; INSULIN; MALONALDEHYDE; MELATONIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; SUPEROXIDE DISMUTASE; ANTIOXIDANT; HOMEODOMAIN PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 9; PANCREATIC AND DUODENAL HOMEOBOX 1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; TRANSACTIVATOR PROTEIN;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INS 1 CELL LINE; INSULIN RESISTANCE; INTERMITTENT HYPOXIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PROTEIN EXPRESSION; RAT; SLEEP DISORDERED BREATHING; ANIMAL; CELL HYPOXIA; CELL LINE; DRUG EFFECTS; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; CELL HYPOXIA; CELL LINE; HOMEODOMAIN PROTEINS; MALONDIALDEHYDE; MELATONIN; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; OXIDATIVE STRESS; RATS; RNA, MESSENGER; SUPEROXIDE DISMUTASE; TRANS-ACTIVATORS;

EID: 84902188610     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. REICHMUTH KJ, AUSTIN D, SKATRUD J.B., YOUNG T. Association of sleep apnea and type 2 diabetes: A population-based study. Am J Respir Crit Care Med 2005; 172: 1590-1595. (Pubitemid 43076551)
2. LAVIE L. Obstructive sleep apnoea syndrome an oxidative stress disorder. Sleep Med Rev 2003; 7: 35-51. (Pubitemid 36188305)
3. FURUKAWA S, FUJITA T, SHIMABUKURO M., IWAKI M, YAMA-DA Y, NAKAJIMA Y, NAKAYAMA O., MAKISHIMA M, MATSU-DA M, SHIMOMURA I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761. (Pubitemid 40385531)
4. IIYORI N, ALONSO LC, LI J, SANDERS M.H., GARCIA-OCANA A, O'DOHERTY RM, POLOTSKY VY, O'DONNELL C P. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007; 175: 851-857. (Pubitemid 46631798)
5. SUDNIKOVICH EJ, MAKSIMCHIK YZ, ZABRODSKAYA S V, KUBYSHIN VL, LAPSHINA E.A., BRYSZEWSKA M., REITER RJ, ZAVODNIK IB. Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. Eur J Pharmacol 2007; 569: 180-187. (Pubitemid 47208514)
6. GUANG L, GANG H, WEI L., JIAN K. Melatonin protects mice with intermittent hypoxia from oxidative stress-induced pancreatic injury. Sleep Biol Rhythms 2011; 9: 78-85.
7. GILMARTIN GS, LYNCH M, TAMISIER R., WEISS JW Chronic intermittent hypoxia in humans during 28 nights results in blood pressure elevation and increased muscle sympathetic nerve activity. Am J Physiol Heart Circ Physiol 2010; 299: H925-931.
8. MA S, MIFFLIN SW, CUNNINGHAM J.T., MORILAK DA Chronic intermittent hypoxia sensitizes acute hy-pothalamic-pituitary-adrenal stress reactivity and Fos induction in the rat locus coeruleus in response to subsequent immobilization stress. Neuroscience 2008; 154: 1639-1647.
9. ZAMARRON C, GARCÍA PAZ V, RIVEIRO A. Obstructive sleep apnea syndrome is a systemic disease. Current evidence. Eur J Intern Med 2008; 19: 390-398.
10. ROBERTSON R.P., HARMON J, TRAN P.O., TANAKA Y., TAKA-HASHI H. Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glu-tathione connection. Diabetes 2003; 52: 581-587. (Pubitemid 36323562)
11. FRIDLYAND LE, PHIPSON LH Oxidative reactive species in cell injury: Mechanism in diabetes mel-litus therapeutic approaches. Ann N Y Acad Sci 2005; 1066: 136-151.
12. OTA H, TAMAKI S, ITAYA-HIRONAKA A, YAMAUCHI A., SAKURAMOTO-TSUCHIDA S, MORIOKA T, TAKASAWA S., KIMURA H. Attenuation of glucose-induced insulin secretion by intermittent hypoxia via down-regulation of CD38. Life Sci 2012; 90: 206-211.
13. LIU HG, ZHANG Z F, ZHANG ZX, GAO Y P, NIU RJ. The change and mechanism of apoptosis in the hip-pocampal CA1 region of rats exposed to intermittent hypoxia. Zhonghua Jie He He Hu Xi Za Zhi 2007; 30: 368-371.
14. XU J, LONG YS, GOZAL D, EPSTEIN PN Beta-cell death and proliferation after intermittent hypoxia: role of oxidative stress. Free Radic Biol Med 2009; 46: 783-790.
15. KANETO H, XU G, FUJII N., KIM S, BONNER-WEIR S, WEIR GC Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem 2002; 277: 30010-30018.
16. KANETO H, KAWAMORI D, MATSUOKA T.A., KAJIMOTO Y., YAMASAKI Y. Oxidative Stress and Pancreatic β-Cell Dysfunction. Am J Ther 2005; 12: 529-533. (Pubitemid 41689753)
17. VARONA-SANTOS J.L., PILEGGI A, MOLANO R.D., SANABRIA NY, IJAZ A, ATSUSHI M, ICHII H., PASTORI RL, INVERARDI L, RICORDI C, FORNONI A. c-Jun N-terminal kinase 1 is deleterious to the function and survival of murine pancreatic islets. Diabetologia 2008; 51: 2271-2280.
18. ZHANG S, LIU J, DRAGUNOW M., COOPER GJ Fibrillo-genic Amylin Evokes Islet β-Cell Apoptosis through Linked Activation of a Caspase Cascade and JNK1. J Biol Chem 2003; 278: 52810-52819. (Pubitemid 38035879)
19. PESCHKE E. Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008; 44: 26-40. (Pubitemid 350231107)
20. PESCHKE E, FRESE T, CHANKIEWITZ E., PESCHKE D, PREISS U, SCHNEYER U., SPESSERT R, MÜHLBAUER E. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res 2006; 40: 135-143.
21. KEMP DM, UBEDA M, HABENER JF Identification and functional characterization of melatonin Mel 1a receptors in pancreatic beta-cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol Cell Endocrinol 2002; 191: 157-166. (Pubitemid 34626621)
22. PESCHKE E. Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008; 44: 26-40. (Pubitemid 350231107)
23. SHAGIRTHA K, MUTHUMANI M, MI LTONPRABU S. Mela-tonin abrogates cadmium induced oxidative stress related neurotoxicity in rats. Eur Rev Med Pharmacol Sci 2011; 15: 1039-1050.
24. AYDEMIR S, OZDEMIR I, KART A. Role of exogenous melatonin on adriamycin-induced changes in the rat heart. Eur Rev Med Pharmacol Sci 2010; 14: 435-441.
25. HERNÁNDEZ C., ABREU J, ABREU P., CASTRO A, JIMÉNEZ A. Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP. Eur Respir J 2007; 30: 496-500. (Pubitemid 351182073)
26. HUNG MW, TIPOE GL, POON A.M., REITER RJ, FUNG ML Protective effect of melatonin against hippocam-pal injury of rats with intermittent hypoxia. J Pineal Res 2008; 44: 214-221. (Pubitemid 351252925)
27. NG KM, LAU C F, FUNG ML Melatonin reduces hip-pocampal beta-amyloid generation in rats exposed to chronic intermittent hypoxia. Brain Res 2010; 1354: 163-171.
28. BERTUGLIA S, REITER RJ Melatonin reduces mi-crovascular damage and insulin resistance in hamsters due to chronic intermittent hypoxia. J Pineal Res 2009; 46: 307-313.